Trial Profile
A Phase I Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Aug 2014
Price :
$35
*
At a glance
- Drugs Sibrotuzumab I-131 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 07 Aug 2014 New trial record